GT Biopharma Discloses Nasdaq Listing Non-Compliance, Granted Extension
GTBP sits 69% above its 52-week low of $0.261.
Summary
GT Biopharma disclosed that it failed to meet Nasdaq's minimum $1.00 bid price requirement. The company has been granted an additional 180-day period, until November 16, 2026, to regain compliance. This compliance issue follows a series of recent negative financial disclosures, including a reiterated going concern warning, restatement of past financials, and significant share dilution. The ongoing struggle to maintain Nasdaq listing standards underscores the company's precarious financial position.
At the time of this announcement, GTBP was trading at $0.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.6M. The 52-week trading range was $0.26 to $3.85. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.